INS and type 1 diabetes mellitus: GzmB increases inflammation in type 1 and type 2 diabetes [162] and impairs insulin secretion from islet cells [163] as part of the mechanism by which it kills pancreatic β cells in the development of type 1 diabetes [162, 164].